{"id":"hydration-plus-rosuvastatin-therapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Elevated liver enzymes"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rosuvastatin is a statin that inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, thereby lowering LDL cholesterol and triglycerides. The addition of hydration therapy aims to optimize fluid balance and potentially improve drug efficacy and tolerability, particularly in hospitalized or acute care settings.","oneSentence":"Hydration plus rosuvastatin therapy combines fluid replacement with HMG-CoA reductase inhibition to improve hydration status and reduce cholesterol synthesis.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:23:24.918Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypercholesterolemia and dyslipidemia management in hospitalized patients requiring fluid resuscitation"}]},"trialDetails":[{"nctId":"NCT04817904","phase":"PHASE2","title":"Evaluation of the Effect of Rosuvastatin on Cisplatin-induced Nephrotoxicity and Ototoxicity","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2020-11-17","conditions":"Cisplatin Adverse Reaction","enrollment":65},{"nctId":"NCT03526367","phase":"PHASE4","title":"A Randomized Trial of Rosuvastatin Loading Combined With Early hydrAtion Versus Standard-of-care Medications for the Prevention of CIAKI in Patient With AMI Undergoing Emergency PCI","status":"WITHDRAWN","sponsor":"Shenyang Northern Hospital","startDate":"2019-02-20","conditions":"Contrast-induced Acute Kidney Injury, ST Elevation Myocardial Infarction, Primary PCI","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"hydration plus rosuvastatin therapy","genericName":"hydration plus rosuvastatin therapy","companyName":"Shenyang Northern Hospital","companyId":"shenyang-northern-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Hydration plus rosuvastatin therapy combines fluid replacement with HMG-CoA reductase inhibition to improve hydration status and reduce cholesterol synthesis. Used for Hypercholesterolemia and dyslipidemia management in hospitalized patients requiring fluid resuscitation.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}